1. |
Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg, 2014, 140(4):317-322.
|
2. |
杨雷, 王宁. 甲状腺癌流行病学研究进展. 中华预防医学杂志, 2014, 48(8):744-748.
|
3. |
袁昊绪. 恶性肿瘤仍占北京市民死亡原因首位. 首都医药, 2014, 15:31-32.
|
4. |
李科, 林国桢, 周琴, 等. 2000-2011年广州市城区甲状腺癌的发病趋势分析. 中华预防医学杂志, 2015. 49(2):142-146.
|
5. |
Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab, 2006, 91(1):313-319.
|
6. |
Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy. J Clin Endocrinol Metab, 2006, 91(8):2892-2899.
|
7. |
Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma:a 15-year median follow-up study. J Clin Endocrinol Metab, 2008, 93(10):3943-3949.
|
8. |
Husain M, Alsever RN, Lock JP, et al. Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. Horm Res, 1978, 9(1):22-25.
|
9. |
Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer:molecular pathogenesis and emerging therapies. Endocr Relat Cancer, 2009, 16(1):17-44.
|
10. |
Smith NR, Baker D, James NH, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res, 2010, 16(14):3548-3561.
|
11. |
Zarebczan B, Chen H. Multi-targeted approach in the treatment of thyroid cancer. Minerva Chir, 2010. 65(1):59-69.
|
12. |
Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest, 2005, 115(4):1068-1081.
|
13. |
Knauf JA, Kuroda H, Basu S, et al. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene, 2003, 22(28):4406-4412.
|
14. |
Nucera C, Porrello A, Antonello ZA, et al. B-Raf (V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA, 2010, 107(23):10649-10654.
|
15. |
Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma[corrected]. Science, 2000, 289(5483):1357-1360.
|
16. |
Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol, 2011, 7(10):569-580.
|
17. |
Thomas L, Lai SY, Dong W, et al. Sorafenib in metastatic thyroid cancer:a systematic review. Oncologist, 2014, 19(3):251-258.
|
18. |
Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial. Lancet, 2014, 384(9940):319-328.
|
19. |
Zhang L, Zhou Q, Ma L, et al. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol, 2011, 36(4):344-350.
|
20. |
Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res, 2009, 15(4):1411-1416.
|
21. |
Boudou-Rouquette P, Ropert S, Mir O, et al. Variability of sorafenib toxicity and exposure over time:a pharmacokinetic/pharmacodynamic analysis. Oncologist, 2012, 17(9):1204-1212.
|
22. |
Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized, double-blind phase Ⅲtrial. J Clin Oncol, 2012, 30(2):134-141.
|
23. |
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine, 2015, 372(7):621-630.
|
24. |
Carr LL, Mankoff DA, Goulart BH, et al. Phase Ⅱ study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res, 2010, 16(21):5260-5268.
|
25. |
Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 2 trial. Lancet Oncol, 2012, 13(9):897-905.
|
26. |
Locati LD, Licitra L, Agate L, et al. Treatment of advanced thyroid cancer with axitinib:Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer, 2014, 120(17):2694-2703.
|
27. |
St Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology, 2005, 146(3):1145-1153.
|
28. |
Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol, 2011, 29(19):2660-2666.
|
29. |
Karras S, Pontikides N, Krassas GE. Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer. Expert Opin Drug Metab Toxicol, 2013, 9(4):507-515.
|
30. |
Giunti S, Antonelli A, Amorosi A, et al. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol, 2013, 2013:803171.
|
31. |
Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol, 2013, 31(29):3639-3646.
|
32. |
Patson B, B Cohen R, Olszanski AJ. Pharmacokinetic evaluation of axitinib. Expert Opin Drug Metab Toxicol, 2012, 8(2):259-270.
|
33. |
Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase Ⅱ efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res, 2012, 18(7):2056-2065.
|
34. |
Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med, 2013, 368(7):623-632.
|
35. |
Wein R, Colombo J. Cabozantinib for progressive metastatic medullary thyroid cancer:a review. Ther Clin Risk Manag, 2014, 10:395-404.
|
36. |
Verbeek HH, Alves MM, de Groot JW, et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab, 2011, 96(6):E991E995.
|
37. |
Dadu R, Devine C, Hernandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab, 2014, 99(6):2086-2094.
|